Background: Fabry disease (FD) is an X-linked lysosomal storage disorder resulting from lack of alpha-galactosidase A (AGALA) activity in lysosomes. Objective: In this multicenter study, we aimed to evaluate the prevalence of FD in renal transplant (Tx) recipients in Turkey. We also screened dialysis patients as a control group. Methods: All Tx and dialysis patients were screened regardless of the presence of a primary disease. We measured the AGALA activity in all male patients as initial analysis. Mutation analysis was performed in male patients with decreased AGALA activity and in female patients as the initial diagnostic assay. Results: We screened 5,657 patients. A total of 17 mutations were identified. No significant difference was observed between the groups regarding the prevalence of patients with mutation. We found FD even in patients with presumed primary kidney diseases. Seventy-one relatives were analyzed and mutation was detected in 43 of them. We detected a patient with a new, unknown mutation (p.Cys223) in the GLA gene. Conclusions: There are important implications of the screening. First, detection of the undiagnosed patients leads to starting appropriate therapies for these patients. Second, the transmission of the disease to future generations may be prevented by prenatal screening after appropriate genetic counseling. In conclusion, we suggest screening of kidney Tx candidates for FD, regardless of etiologies of chronic kidney disease.

Keywords:
Alpha-galactosidase A, Fabry disease, Family screening, Index case, Renal transplant recipient
1.
Kint JA: Fabry’s disease: alpha-galactosidase deficiency. Science 1970; 167: 1268–1269.
2.
Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, Handsaker RE, et al: An integrated map of genetic variation from 1,092 human genomes. Nature 2012;491: 56–65.
3.
Saito S, Ohno K, Sakuraba H: Fabry-database.org: database of the clinical phenotypes, genotypes and mutant α-galactosidase a structures in fabry disease. J Hum Genet 2011; 56: 467–468.
4.
The Human Gene Mutation Database at the Institute of Medical Genetics in Cardiff. http://www. hgmd. cf. ac. Uk (cited November 20, 2018).
5.
Zarate YA, Hopkin RJ: Fabry’s disease. Lancet 2008; 372: 1427–1435.
6.
Mechtler TP, Stary S, Metz TF, De Jesús VR, Greber-Platzer S, Pollak A, et al: Neonatal screening for lysosomal storage disorders: feasibility and incidence from a nationwide study in Austria. Lancet 2012; 379: 335–341.
7.
Spada M, Pagliardini S, Yasuda M, Tukel T, Thiagarajan G, Sakuraba H, et al: High incidence of later-onset fabry disease revealed by newborn screening. Am J Hum Genet 2006; 79: 31–40.
8.
Shi Q, Chen J, Pongmoragot J, Lanthier S, Saposnik G: Prevalence of Fabry disease in stroke patients – a systematic review and meta-analysis. J Stroke Cerebrovasc Dis 2014; 23: 985–992.
9.
Baptista A, Magalhães P, Leão S, Carvalho S, Mateus P, Moreira I: Screening for Fabry disease in left ventricular hypertrophy: documentation of a novel mutation. Arq Bras Cardiol 2015; 105: 139–144.
10.
Linthorst GE, Bouwman MG, Wijburg FA, Aerts JM, Poorthuis BJ, Hollak CE: Screening for Fabry disease in high-risk populations: a systematic review. J Med Genet 2010; 47: 217–222.
11.
Andrade J, Waters PJ, Singh RS, Levin A, Toh BC, Vallance HD et al: Screening for Fabry disease in patients with chronic kidney disease: limitations of plasma alpha-galactosidase assay as a screening test. Clin J Am Soc Nephrol 2008; 3: 139–145.
12.
Reese PP, Boudville N, Garg AX: Living kidney donation: outcomes, ethics, and uncertainty. Lancet 2015; 385: 2003–2013.
13.
Horvat LD, Shariff SZ, Garg AX; Donor Nephrectomy Outcomes Research (DONOR) Network: Global trends in the rates of living kidney donation. Kidney Int 2009; 75: 1088–1098.
14.
Seyahi N, Ateş K, Süleymanlar G: Current status of renal replacement therapies in Turkey: Turkish society of nephrology registry 2015 summary report. Turk Neph Dial Transpl 2017; 26: 154–160.
15.
Turkish Statistical Institute database. Endogamy ratio in Turkey. www.tuik.gov.tr/HbPrint.do?id=24646 (cited July 15, 2018).
16.
Chamoles NA, Blanco M, Gaggioli D: Fabry disease: enzymatic diagnosis in dried blood spots on filter paper. Clin Chim Acta 2001; 308: 195–196.
17.
Lukas J, Giese AK, Markoff A, Grittner U, Kolodny E, Mascher H, et al: Functional characterisation of alpha-galactosidase a mutations as a basis for a new classification system in fabry disease. PLoS Genet 2013; 9:e1003632.
18.
Hasholt L, Ballegaard M, Bundgaard H, Christiansen M, Law I, Lund AM, et al: The D313Y variant in the GLA gene – no evidence of a pathogenic role in Fabry disease. Scand J Clin Lab Invest 2017; 77: 617–621.
19.
Niemann M, Rolfs A, Giese A, Mascher H, Breunig F, Ertl G, et al: Lyso-Gb3 indicates that the alpha-galactosidase a mutation D313Y is not clinically relevant for Fabry disease. JIMD Rep 2013; 7: 99–102.
20.
Maixnerová D, Tesař V, Ryšavá R, Reiterová J, Poupětová H, Dvořáková L, et al: The coincidence of IgA nephropathy and Fabry disease. BMC Nephrol 2013; 14: 6.
21.
Liu Y, Xie H, Lin H, Chen S, Wang W, Zhao G, et al: Coexistence of Fabry disease and membranous nephropathy. Iran J Kidney Dis 2016; 10: 48–50.
22.
Svarstad E, Bostad L, Kaarbøe O, Houge G, Tøndel C, Lyngdal PT, et al: Focal and segmental glomerular sclerosis (FSGS) in a man and a woman with Fabry’s disease. Clin Nephrol 2005; 63: 394–401.
23.
Cai ZY, Zhang YK, Wang SX, Fang QY, Chen YQ: Diffuse thin glomerular basement membrane in association with Fabry disease in a Chinese female patient. Nephrol Dial Transplant 2011; 26: 3813–3816.
24.
Herrera J, Miranda CS: Prevalence of Fabry’s disease within hemodialysis patients in Spain. Clin Nephrol 2014; 81: 112–120.
25.
Thadhani R, Wolf M, West ML, Tonelli M, Ruthazer R, Pastores GM, et al: Patients with Fabry disease on dialysis in the United States. Kidney Int 2002; 61: 249–255.
26.
Porsch DB, Nunes AC, Milani V, Rossato LB, Mattos CB, Tsao M, et al: Fabry disease in hemodialysis patients in southern Brazil: prevalence study and clinical report. Ren Fail 2008; 30: 825–830.
27.
Gaspar P, Herrera J, Rodrigues D, Cerezo S, Delgado R, Andrade CF, et al: Frequency of Fabry disease in male and female haemodialysis patients in Spain. BMC Med Genet 2010; 11: 19.
28.
Saito O, Kusano E, Akimoto T, Asano Y, Kitagawa T, Suzuki K, et al: Prevalence of Fabry disease in dialysis patients: Japan Fabry disease screening study (J-FAST). Clin Exp Nephrol 2016; 20: 284–293.
29.
De Schoenmakere G, Poppe B, Wuyts B, Claes K, Cassiman D, Maes B, et al: Two-tier approach for the detection of alpha-galactosidase a deficiency in kidney transplant recipients. Nephrol Dial Transplant 2008; 23: 4044–4048.
30.
Kleinert J, Kotanko P, Spada M, Pagliardini S, Paschke E, Paul K, et al: Anderson-Fabry disease: a case-finding study among male kidney transplant recipients in Austria. Transpl Int 2009; 22: 287–292.
31.
Yılmaz M, Uçar SK, Aşçı G, Canda E, Tan FA, Hoşcoşkun C, et al: Preliminary screening results of Fabry disease in kidney transplantation patients: a single-center study. Transplant Proc 2017; 49: 420–424.
32.
Caudron E, Prognon P, Germain DP: Enzymatic diagnosis of Fabry disease using a fluorometric assay on dried blood spots: an alternative methodology. Eur J Med Genet 2015; 58: 681–684.
33.
Finsterer J, Stöllberger C, Voigtländer T: Comparison of two tests for serum alpha-galactosidase in nonneuromuscular left ventricular hypertrabeculation/concompaction. Jpn Heart J 2004; 45: 179–181.
34.
Oemardien LF, Boer AM, Ruijter GJ, van der Ploeg AT, de Klerk JB, Reuser AJ, et al: Hemoglobin precipitation greatly improves 4-methylumbelliferone-based diagnostic assays for lysosomal storage diseases in dried blood spots. Mol Genet Metab 2011; 102: 44–48.
35.
Lyon MF: Gene action in the X-chromosome of the mouse (Mus musculus L.). Nature 1961; 190: 372–337.
36.
Kalkan Uçar S, Sozmen E, Duman S, Başçi A, Çoker M: Alpha-galactosidase a activity levels in Turkish male hemodialysis patients. Ther Apher Dial 2012; 16: 560–565.
37.
Kabalan SN, Abbas S, Tawil L: A search for Fabry disease among male end-stage renal disease patients in Lebanon and a review of the literature. J Med Liban 2013; 61: 144–147.
38.
Yeniçerioğlu Y, Akdam H, Dursun B, Alp A, Sağlam Eyiler F, Akın D, et al: Screening Fabry’s disease in chronic kidney disease patients not on dialysis: a multicenter study Ren Fail 2017; 39: 104–111.
39.
Altarescu G, Beeri R, Eiges R, Epsztejn-Litman S, Eldar-Geva T, Elstein D, et al: Prevention of lysosomal storage diseases and derivation of mutant stem cell lines by preimplantation genetic diagnosis. Mol Biol Int 2012; 2012: 797342.
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.